• TBX 201

    TBX201 is designed to reduce the incidence and severity of severe diarrhea caused by irinotecan. Irinotecan is a first-line chemotherapy drug for the treatment of several metastatic cancer indications. Clinical use of irinotecan in over 100,000 patients annually is associated with life-threatening toxicity and treatment interruptions for many patients.

  • TBX 301

    TBX301 is designed to prevent the incidence and severity of colitis in patients receiving immune checkpoint inhibitors (ICI). The number of patients receiving treatment with ICI, such as CLTA-4, PD1 or PDL1 inhibitors, is rapidly increasing, with currently over 1 million patients globally treated annually with ICI. Severe life-threatening and treatment-limiting colitis is one of the lead adverse reactions to ICI treatment.